Sugi Predict

Sugi Predict / Compounds / SCHEMBL186196

SCHEMBL186196

SCHEMBL186196

CCOC(=O)C(C)(C)Cc1ccc(C(=O)c2ccc(CC(C)(C)C(=O)OCC)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP8 P22894 1/20 0.47
▸ ELANE P08246 4/20 0.46
▸ ALDH1A1 P00352 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ LMNA P02545 3/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ MAOA P21397 1/20 0.42
▸ CYP4F2 P78329 1/20 0.40
▸ CYP4A11 Q02928 1/20 0.40
▸ SRD5A2 P31213 1/20 0.40
▸ TSHR P16473 2/20 0.40
▸ ABCB11 O95342 1/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21294046 0.93 ALDH1A1 (0.44) MMP8ELANEALDH1A1RECQLOPRK1
SCHEMBL13170332 0.86 MMP8 (0.49) MMP8ALDH1A1RECQLOPRK1LMNA
SCHEMBL22070681 0.85 MMP8 (0.48) MMP8ALDH1A1RECQLOPRK1LMNA
SCHEMBL8486868 0.85 ESR1 (0.50) MMP8ALDH1A1RECQLOPRK1CYP1A2
SCHEMBL1722319 0.84 F2 (0.37) MMP8ELANEALDH1A1RECQLOPRK1
SCHEMBL2906609 0.83 MMP8 (0.47) MMP8ALDH1A1RECQLOPRK1LMNA
SCHEMBL5381952 0.83 MMP8 (0.47) MMP8ALDH1A1RECQLLMNACYP1A2
SCHEMBL2557165 0.83 CYP3A4 (0.58) MMP8ALDH1A1RECQLOPRK1LMNA
SCHEMBL1492859 0.83 MMP8 (0.65) MMP8ALDH1A1RECQLLMNATSHR
SCHEMBL6746893 0.82 MMP8 (0.49) MMP8ALDH1A1RECQLOPRK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006238-A1 Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY 2004-01-08 — — US claimed
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY 2003-11-20 — — US claimed
US-6613944-B2 Reacting phthalimide with an epoxide in the presence of potassium phthalimide in DMF or DMAC to give a phthalimide alkylalcohol, deacylation with aqueous acid PHARMACIA & UPJOHN COMPANY 2003-09-02 — — US claimed
US-20030130509-A1 PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS PHARMACIA & UPJOHN COMPANY 2003-07-10 — — US claimed
US-20030065219-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY 2003-04-03 — — US claimed
US-20020095054-A1 Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY 2002-07-18 — — US claimed
US-20020032348-A1 Process to produce oxazolidinones PEARLMAN BRUCE ALLEN (US) 2002-03-14 — — US claimed
EP-1028940-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2000-08-23 — — EP claimed
WO-1999024393-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1999-05-20 — — WO claimed
US-20230210800-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS INC (US) 2023-07-06 — — US disclosed
US-20210395175-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2021-12-23 — — US disclosed
US-10941095-B2 Hydroxyl compounds and compositions for cholesterol management and related uses ESPERION THERAPEUTICS, INC. (US) 2021-03-09 — — US disclosed
US-20190263742-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2019-08-29 — — US disclosed
US-10118881-B2 Hydroxyl compounds and compositions for cholesterol management and related uses ESPERION THERAPEUTICS, INC. (US) 2018-11-06 — — US disclosed
US-20050043278-A1 administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X GLAS AMERICAS LLC 2005-02-24 — — US disclosed
WO-2004067489-A2 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2004-08-12 — — WO disclosed
EP-1028940-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2000-08-23 — — EP disclosed
WO-1999024393-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1999-05-20 — — WO disclosed
EP-0281018-A1 Heterocyclyl-2-propyn-1-amines MERRELL DOW PHARMACEUTICALS INC. (US) 1988-09-07 — — EP disclosed
US-4743617-A HYPOTENSIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1988-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065219-A1 PROCESS TO PRODUCE OXAZOLIDINONES ADH1A, ADH5, ADH1C MMP8 3260/4885ELANE 4501/4885ALDH1A1 109/4885
US-20030130509-A1 PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS ADH1A, ADH5, ADH1C MMP8 4335/4885ELANE 4384/4885ALDH1A1 73/4885
US-20040006238-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C MMP8 3372/4885ELANE 4489/4885ALDH1A1 142/4885
US-20020095054-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C MMP8 3260/4885ELANE 4501/4885ALDH1A1 109/4885
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES ADH1A, ADH5, ADH1C MMP8 3260/4885ELANE 4501/4885ALDH1A1 109/4885
US-20190263742-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES NR1H3, CYP27A1, NR1H2 MMP8 897/4885ELANE 1498/4885ALDH1A1 1480/4885
US-10941095-B2 Hydroxyl compounds and compositions for cholesterol management and related uses NR1H3, CYP27A1, NR1H2 MMP8 897/4885ELANE 1498/4885ALDH1A1 1480/4885
US-20210395175-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES NR1H3, CYP27A1, NR1H2 MMP8 897/4885ELANE 1498/4885ALDH1A1 1480/4885
US-20230210800-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES CYP27A1, NR1H3, PNLIP MMP8 753/4885ELANE 827/4885ALDH1A1 1603/4885
US-10118881-B2 Hydroxyl compounds and compositions for cholesterol management and related uses NR1H3, CYP27A1, NR1H2 MMP8 897/4885ELANE 1498/4885ALDH1A1 1480/4885
US-20020032348-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C MMP8 3260/4885ELANE 4501/4885ALDH1A1 109/4885
US-20050043278-A1 administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X PNLIP, NR1H3, CYP27A1 MMP8 950/4885ELANE 1135/4885ALDH1A1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.